Donald L. Durden

Also affiliated with Atrium Medical Cente, Wake Forest University

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity”.

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

Cell Discovery(2020)10.1038/s41421-020-0181-z

N/A

0.416DataRank · unranked

15 citations

Kendra R. Vann, Shweta Joshi, Guillermo Morales, Francisco M. De La Vega, Alok Singh +5 more

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

iScience(2021)10.1016/j.isci.2021.102931

N/A

0.406DataRank · unranked

14 citations

Kendra R. Vann, Shweta Joshi, Namood-e Sahar, Guillermo Morales, Dalia El‐Gamal +3 more

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2023.2256914

N/A

0.208DataRank · unranked

3 citations

Dhananjaya Pal, Rolando Martinez-Rico, Alexandria P. Eiken, Donald L. Durden, Tatiana G. Kutateladze +2 more

Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma

Journal of Pediatric Hematology/Oncology(2021)10.1097/mph.0000000000002054

N/A

0DataRank · unranked

7 citations

Alok Singh, Shweta Joshi, Christina Jamieson, Donald L. Durden, Amanda N. Goldin

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

Frontiers in Oncology(2021)10.3389/fonc.2021.766888

N/A

0DataRank · unranked

2 citations

Hye Na Kim, Heather Ogana, Zesheng Wan, Samantha Hurwitz, Cydney Nichols +14 more

Blockade of SARS-CoV-2 infection in vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.03.02.433604

N/A

0DataRank · unranked

13 citations

Kabita Pandey, Michellie Thurman, Kishore B. Challagundala, Kendra R. Vann, Tatiana G. Kutateladze +4 more

Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection

Structure(2022)10.1016/j.str.2022.05.020

N/A

0DataRank · unranked

33 citations

Arpan Acharya, Suk Min Jang, Catherine Lachance, Mohamad Zandian, Tina Holt +8 more

LC–MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies

Biomedical Chromatography(2023)10.1002/bmc.5643

N/A

0DataRank · unranked

3 citations

Yashpal S. Chhonker, Guillermo Morales, Maddeboina Krishnaiah, Dhananjaya Pal, Donald L. Durden +2 more

Novel multitarget small molecule inhibitor LCI133 and synthetic lethality in endometrial carcinoma via CDK9/PI3K axis.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15118

N/A

0DataRank · unranked

2 citations

Dhananjaya Pal, Maddeboina Krishnaiah, R. Wendel Naumann, Erin K. Crane, Jubilee Brown +7 more

Recent advances in multitarget-directed ligands via in silico drug discovery

Drug Discovery Today(2024)10.1016/j.drudis.2024.103904

N/A

0DataRank · unranked

27 citations

Bharath Yada, Shikha Kumari, Cody McHale, Dhananjaya Pal, Donald L. Durden +1 more

SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2

Antiviral Research(2024)10.1016/j.antiviral.2024.105904

N/A

0DataRank · unranked

3 citations

Arpan Acharya, Dhananjaya Pal, Prashant Jain, Kamalendra Singh, Donald L. Durden +4 more

Discovery of a “First-in-Class” Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c01688

N/A

0DataRank · unranked

3 citations

Dhananjaya Pal, Bharath Yada, Cody McHale, Sandeep Kumar Singh, Yashpal S. Chhonker +7 more

COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges

Theranostics(2020)10.7150/thno.51471

N/A

0DataRank · unranked

129 citations

Philip Prathipati, Bakrudeen AA. Abdul, Srinivas Chava, Santharam S. Katta, Subash Gupta +6 more

TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas

iScience(2025)10.1016/j.isci.2025.112584

N/A

0DataRank · unranked

2 citations

Samon Benrashid, M. Templeton, Lawrence J. Druhan, Sara L. Seegers, Supriya Chakraborty +12 more

Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets

Scientific Reports(2020)10.1038/s41598-020-68964-6

N/A

0DataRank · unranked

12 citations

Dhananjaya Pal, Guillermo Morales, Adam M. Burgoyne, Donald L. Durden, Tatiana G. Kutateladze +1 more

Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity

UNC Libraries(2020)10.17615/mx51-6586

N/A

0DataRank · unranked

0 citations

Carol Tucker‐Burden, Donald L. Durden, Jeffrey J. Olson, Erwin G. Van Meir, Daniel J. Brat +4 more